Project Grant K99DA059612
- This $1,039,420 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to study the neuronal ensembles and circuits involved in the facilitation and disinhibition of opioid and alcohol seeking behaviors. The 5-year project, which begins on June 1, 2025 and runs through February 28, 2030, will employ innovative techniques such as single-nucleus RNA sequencing, spatial sequencing, and in vivo...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $159,615.00 to the Icahn School of Medicine at Mount Sinai for a research project titled "Predicting Craving and Relapse Using Neurobehavioral Markers of Goals and Habits in Opioid Use Disorder". The primary objectives of the research are to track daily changes in motivational control during opioid addiction treatment, and use these...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...
- This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
- This federal Project Grant award of $650,250 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to investigate the neural mechanisms underlying motivational and cognitive deficits associated with opioid withdrawal. The project aims to uncover the role of dopamine and acetylcholine signaling, as well as the activity of striatal projection neurons, in mediating withdrawal-induced reductions in motivation and...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is providing $903,965 to the University of Alabama at Birmingham (UAB) to conduct research on prefrontal circuits controlling heroin seeking behavior. The project aims to identify two functionally opposing prefrontal subcircuits that drive versus limit opioid seeking, with a focus on understanding the role of the infralimbic prefrontal cortex...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $787,594.00 to the Icahn School of Medicine at Mount Sinai to conduct research on the "Cortical Mechanisms of Opioid Reinforcement." The research aims to better understand the molecular, cellular, and circuit-based mechanisms underlying opioid use disorder (OUD). Specifically, the study will investigate the role of a specialized...
- This Project Grant award, valued at $223,176.00 and provided by the National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, aims to examine the modulatory role of the neuropeptide galanin in opioid reward under the NIDA's Drug Use and Addiction Research Programs (CFDA 93.279). The research, to be conducted by Emory University in Atlanta, Georgia, seeks to identify the source of endogenous galanin in the ventral tegmental area (VTA) that opposes opioid...
- This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $109,076 to Trustees of Boston University to conduct research on the role of the G alpha Z (Gaz) protein in opioid-induced behavioral responses. The project aims to utilize conditional knockout models to investigate the regional effects of Gaz signaling in the ventrolateral periaqueductal gray and nucleus accumbens on the analgesic, rewarding, and...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,351,034 to the University of Alabama at Birmingham (UAB) to study the role of somatostatin-expressing interneurons in the prelimbic region of the rodent medial prefrontal cortex and their involvement in natural and drug reward seeking behaviors. The award, with a project period from Apr 15, 2025...
INVESTIGATION INTO THE FUNCTION OF HYPOTHALAMIC GABA AND GLUTAMATE IN MOTIVATION FOR OPIOID REWARD - PROJECT SUMMARY/ABSTRACT OPIOID USE HAS REACHED EPIDEMIC PROPORTIONS AND IS NOW THE LEADING CAUSE OF PREVENTABLE DEATH IN THE UNITED STATES. BEYOND THE RISK OF DEATH, OPIOID USE DISORDER CAUSES AN INCALCULABLE AMOUNT OF SUFFERING AS IT DEVASTATES THE LIVES OF INDIVIDUALS AND THEIR COMMUNITIES. THE HEIGHTENED MOTIVATION FOR DRUG REWARDS COMPARED TO NON- DRUG REWARDS STEMS IN PART FROM CHANGES IN THE BRAIN CIRCUITY ASSOCIATED WITH MOTIVATION. A GREATER UNDERSTANDING OF THIS CIRCUITRY MAY LEAD TO TARGETED INTERVENTIONS THAT CAN ATTENUATE DRUG MOTIVATION. DECADES OF RESEARCH DEMONSTRATE THAT THE LATERAL HYPOTHALAMUS (LHA), AND ITS MODULATION OF THE DOPAMINE SYSTEM, PLAYS A CRUCIAL ROLE MOTIVATION. MULTIPLE SPECIES OF ANIMALS WILL WORK TIRELESSLY TO OBTAIN ELECTRICAL STIMULATION OF THE LHA, AND LESIONS OF THE LHA REDUCE MOTIVATION ACROSS A BROAD SPECTRUM OF BEHAVIORS. RECENT RESEARCH HAS REVEALED COMPLEXITY IN THE FUNCTION OF THE LHA, AS SUBPOPULATIONS OF NEURONS CAN DRIVE DISCRETE OR EVEN OPPOSING BEHAVIORAL PHENOTYPES. DESPITE THE ESTABLISHED ROLE IN MOTIVATION BROADLY, THE ROLE OF THE LHA SUBPOPULATIONS IN MOTIVATION FOR OPIOIDS REMAINS LARGELY UNKNOWN. THIS PROPOSAL SEEKS TO INVESTIGATE THE BEHAVIORAL FUNCTION AND SPATIOTEMPORAL SIGNALING DYNAMICS OF MULTIPLE LHA SUBPOPULATIONS AND DOWNSTREAM DOPAMINERGIC SIGNALING DURING THE DEVELOPMENT AND EXPRESSION OF MOTIVATION FOR OPIOIDS. DURING THE K99 PERIOD, I WILL RECEIVE WORLD-CLASS TRAINING IN THE THEORY OF OPIOID PHARMACOLOGY AND SELF-ADMINISTRATION, TECHNIQUES FOR LONGITUDINAL RECORDING USING 2-PHOTON IMAGING, AND ADVANCED ANALYSIS OF THE RELATIONSHIPS BETWEEN NEURONAL SIGNALING DYNAMICS AND BEHAVIOR. IN AIM 1 (K99), I WILL DETERMINE THE CAUSAL BEHAVIORAL FUNCTION OF MULTIPLE LHA SUBPOPULATIONS DURING MOTIVATION FOR OPIOIDS USING TRANSIENT INHIBITION OR EXCITATION OF NEUROTRANSMITTER DEFINED NEURON POPULATIONS. IN AIM 2 (K99), I WILL DETERMINE THE RELATION BETWEEN BULK SIGNALING DYNAMICS IN THE LHA SUBPOPULATIONS AND DOWNSTREAM DOPAMINE SIGNALING USING FIBER-PHOTOMETRY AND THE SINGLE CELL DYNAMICS OF LHA SUBPOPULATIONS USING 2-PHOTON IMAGING THROUGHOUT THE DEVELOPMENT AND EXPRESSION MOTIVATION FOR OPIOIDS. BY RECORDING THROUGHOUT THE EXPERIMENT, I WILL HAVE THE POWER TO CHARACTERIZE BULK AND SINGLE-CELL SIGNALS BASED ON ACTIVITY ACROSS EACH STAGE OF OPIOID SELF-ADMINISTRATION. IN AIM 3 (R00), AS I TRANSITION TO DEVELOPING MY OWN RESEARCH LAB, I WILL INVESTIGATE THE CAUDAL CIRCUIT EFFECTS OF TRANSIENT STIMULATION OF LHA SUBPOPULATIONS DURING MOTIVATION FOR OPIOIDS. ALTOGETHER, THE RESULTS OF THE PROPOSED AIMS WILL DEEPEN OUR UNDERSTANDING OF THE ROLE OF THE LHA IN MEDIATING MOTIVATION FOR DRUGS OF ABUSE AND RELATED NEURONAL CIRCUITRY. THE TRAINING I WILL RECEIVE THROUGHOUT THE K99/R00 PERIOD WILL FACILITATE MY DEVELOPMENT INTO AN INDEPENDENT RESEARCHER INVESTIGATING THE BEHAVIORAL FUNCTION AND SPATIOTEMPORAL SIGNALING DYNAMICS RELATED TO SUBSTANCE USE DISORDER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $173.2k | 5/28/25 | ||
| Not listed | $173.2k | 7/5/24 | ||
| Not listed | $173.2k | 7/5/24 |